Crinetics Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Crinetics Pharmaceuticals kazanç ve gelirin sırasıyla yıllık 51.3% ve 54.1% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 50% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -33.5% olacağı tahmin edilmektedir.

Anahtar bilgiler

51.3%

Kazanç büyüme oranı

50.01%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	14.4%
Gelir büyüme oranı	54.1%
Gelecekteki özkaynak getirisi	-33.52%
Analist kapsamı	Good
Son güncelleme	11 May 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Analiz Makalesi • May 13

Industry Analysts Just Upgraded Their Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Revenue Forecasts By 11%

Crinetics Pharmaceuticals, Inc. ( NASDAQ:CRNX ) shareholders will have a reason to smile today, with the analysts...

Seeking Alpha • Oct 30

Crinetics Pharmaceuticals: Its Post-FDA Approval Future

Summary Crinetics Pharmaceuticals (CRNX) stock has surged after FDA approval of Palsonify for acromegaly, unlocking a potential $1.5–$2.2B market and future label expansion. Palsonify offers superior efficacy and convenience versus competitors, positioning CRNX for rapid adoption despite a crowded treatment landscape and modest patient numbers. Pipeline includes atumelnant for CAH and Cushing’s, with pivotal trials starting in late 2025, but faces competition from Neurocrine’s Crenessity. An analysis around Crinetics Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking Alpha

Analiz Makalesi • Jun 17

A Look At The Intrinsic Value Of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)

Key Insights The projected fair value for Crinetics Pharmaceuticals is US$37.65 based on 2 Stage Free Cash Flow to...

Analiz Makalesi • Apr 23

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Seeking Alpha • Jan 02

Crinetics Pharmaceuticals: Attractive Speculative Bet On Market Weakness

Summary Crinetics Pharmaceuticals is currently overvalued but holds strong Wall Street support with a $75.07 average price target, indicating a 47.43% upside. The FDA accepted Crinetics' NDA for paltusotine, setting a PDUFA date of 09/24/2025. Crinetics is preparing for a fall 2025 launch of paltusotine, engaging with payers and endocrinologists to ensure broad patient access and formulary placement. Despite its valuation, Crinetics' advancements in acromegaly treatment and strong Wall Street backing make it a hold and potential acquisition on pullbacks. Read the full article on Seeking Alpha

Analiz Makalesi • Oct 02

We're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Seeking Alpha • Aug 12

Crinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech

Summary Paltusotine in the treatment of acromegaly is Crinetics lead therapy with NDA filing planned in H2 2024. Crinetics has no approved drug and its lead therapy will face significant competition once approved. Investors should be aware of the high-risk nature of investing in Crinetics Pharmaceuticals. Read the full article on Seeking Alpha

Analiz Makalesi • Jun 01

Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation

Key Insights Crinetics Pharmaceuticals to hold its Annual General Meeting on 7th of June Salary of US$614.0k is part of...

Seeking Alpha • May 23

Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data

Summary Positive data released from 4 patients from phase 2 study that took Atumelnant for congenital adrenal hyperplasia, showing reductions in key biomarkers of A4 and 17-OHP. An NDA submission of Paltusotine for the treatment of patients with Acromegaly expected in the 2nd half of 2024. Additional results from phase 2 open-label study, using Atumelnant for patients with CAH, to be presented at ENDO Conference on June 3rd 2024 at 12:00 to 1:30 p.m. ET. Pending positive talks with FDA, possible initiation of phase 3 study using Paltusotine for the treatment of patients with Carcinoid Syndrome by end of 2024. Read the full article on Seeking Alpha

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:CRNX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2028	420	-285	-220	-339	7
12/31/2027	173	-470	-361	-367	13
12/31/2026	69	-512	-418	-391	13
3/31/2026	18	-496	-420	-414	N/A
12/31/2025	8	-465	-384	-378	N/A
9/30/2025	2	-423	-354	-348	N/A
6/30/2025	1	-370	-306	-300	N/A
3/31/2025	1	-328	-270	-266	N/A
12/31/2024	1	-298	-234	-230	N/A
9/30/2024	1	-278	-206	-202	N/A
6/30/2024	1	-259	-187	-180	N/A
3/31/2024	2	-235	-184	-178	N/A
12/31/2023	4	-215	-173	-169	N/A
9/30/2023	5	-199	-167	-163	N/A
6/30/2023	5	-184	-161	-160	N/A
3/31/2023	4	-175	-144	-142	N/A
12/31/2022	5	-164	-117	-115	N/A
9/30/2022	5	-150	-104	-103	N/A
6/30/2022	5	-136	-91	-90	N/A
3/31/2022	4	-119	-82	-82	N/A
12/31/2021	1	-108	-89	-89	N/A
9/30/2021	N/A	-98	-82	-82	N/A
6/30/2021	N/A	-89	-74	-74	N/A
3/31/2021	N/A	-79	-70	-70	N/A
12/31/2020	0	-74	-62	-62	N/A
9/30/2020	0	-67	-60	-60	N/A
6/30/2020	1	-63	-55	-55	N/A
3/31/2020	1	-59	-52	-52	N/A
12/31/2019	1	-50	N/A	-46	N/A
9/30/2019	2	-44	N/A	-39	N/A
6/30/2019	2	-38	N/A	-31	N/A
3/31/2019	2	-31	N/A	-23	N/A
12/31/2018	2	-27	N/A	-19	N/A
9/30/2018	2	-21	N/A	-16	N/A
6/30/2018	2	-16	N/A	-13	N/A
3/31/2018	2	-12	N/A	-11	N/A
12/31/2017	2	-9	N/A	-9	N/A
12/31/2016	1	-6	N/A	-5	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: CRNX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: CRNX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: CRNX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: CRNX şirketinin gelirinin (yıllık 54.1% ) US pazarından (yıllık 11.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: CRNX şirketinin gelirinin (yıllık 54.1% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: CRNX 3 yıl içinde kârsız olması bekleniyor.

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/21 03:14
Gün Sonu Hisse Fiyatı	2026/05/21 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Crinetics Pharmaceuticals, Inc. 21 Bu analistlerden 13, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Brian Skorney	Baird
Joshua Schimmer	Cantor Fitzgerald & Co.
David Lebowitz	Citigroup Inc

Crinetics Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus revenue estimates increase by 11%

Consensus revenue estimates increase by 12%

Price target increased by 9.8% to US$76.87

Price target decreased by 9.0% to US$68.60

Consensus revenue estimates fall by 23%

Consensus revenue estimates fall by 20%

Recent updates

Consensus revenue estimates increase by 11%

Industry Analysts Just Upgraded Their Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Revenue Forecasts By 11%

Crinetics Pharmaceuticals Reports US$10.3 Million PALSONIFY Launch Revenue and Advances Pipeline

First quarter 2026 earnings: EPS in line with analyst expectations despite revenue beat

Crinetics Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2026

Crinetics Pharmaceuticals, Inc. Announces European Commission Approval of PALSONIFY for Treatment of Acromegaly in Adults

Chief Development & Operating Officer notifies of intention to sell stock

Crinetics Pharmaceuticals, Inc. to Report Q1, 2026 Results on May 07, 2026

Crinetics Pharmaceuticals Submits Marketing Authorization Application for Palsonify in Brazil

Crinetics Pharmaceuticals, Inc. Announces Resignation of Jeff Knight as Chief Development and Operating Officer, Effective on or About April 10, 2026

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Crinetics Pharmaceuticals, Inc. Approves Change in Title and Responsibilities for Jeff Knight, from Chief Operating Officer to Chief Development and Operating Officer, Effective January 2, 2026

Crinetics Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $350.139 million.

Consensus revenue estimates increase by 12%

Crinetics Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $350 million.

Crinetics Pharmaceuticals, Inc. Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia

Founder exercised options to buy US$2.1m worth of stock.

Crinetics Pharmaceuticals, Inc. Announces Resignation of Dana Pizzuti as Chief Medical and Development Officer, Effective from December 31, 2025

Crinetics Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

Crinetics Pharmaceuticals, Inc. Announces First Patient Randomized in Pivotal Phase 3 CarefDR Trial Evaluating Paltusotine in Carinoid Syndrome

Crinetics Pharmaceuticals: Its Post-FDA Approval Future

Crinetics Pharmaceuticals, Inc. to Highlight Neuroendocrine Tumor Research Progress At the 2025 North American Neuroendocrine Tumor Society Annual Meeting

Crinetics Pharmaceuticals, Inc. to Report Q3, 2025 Results on Nov 06, 2025

New minor risk - Share price stability

Independent Director notifies of intention to sell stock

Price target increased by 9.8% to US$76.87

Crinetics Pharmaceuticals, Inc. Announces FDA Approval of Palsonify™? (Paltusotine) for the Treatment of Adults with Acromegaly

Chief Medical & Development Officer notifies of intention to sell stock

Crinetics Pharmaceuticals, Inc. Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia

Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 9.0% to US$68.60

Crinetics Pharmaceuticals, Inc. to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral Palsonify™? (Paltusotine) in Acromegaly At Endocrine Society

Crinetics Pharmaceuticals, Inc. to Report Q2, 2025 Results on Aug 07, 2025

Crinetics Pharmaceuticals, Inc. to Showcase the Next Generation of Endocrinology Innovation At Endocrine Society's Annual Meeting, ENDO 2025

Now 21% undervalued after recent price drop

A Look At The Intrinsic Value Of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Now 20% undervalued after recent price drop

Crinetics Pharmaceuticals, Inc. to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment At the American Association of Clinical Endocrinology Annual Meeting 2025

Consensus revenue estimates fall by 23%

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Crinetics Pharmaceuticals, Inc., Annual General Meeting, Jun 11, 2025

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Crinetics Pharmaceuticals, Inc. to Report Q1, 2025 Results on May 08, 2025

Consensus revenue estimates fall by 20%

Full year 2024 earnings: EPS in line with expectations, revenues disappoint

Crinetics Pharmaceuticals, Inc. Appoints Tobin “Toby” Schilke as Chief Financial Officer, Effective February 28, 2025

Crinetics Pharmaceuticals, Inc. to Report Q4, 2024 Results on Feb 27, 2025

New major risk - Shareholder dilution

Crinetics Announces Positive Topline Results from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (Cah)

Chief Medical & Development Officer exercised options and sold US$528k worth of stock

Crinetics Pharmaceuticals: Attractive Speculative Bet On Market Weakness

Crinetics Pharmaceuticals, Inc. Appoints Isabel Kalofonos as Chief Commercial Officer

Crinetics Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly

Founder notifies of intention to sell stock

Consensus revenue estimates fall by 20%

Third quarter 2024 earnings released: US$0.96 loss per share (vs US$1.01 loss in 3Q 2023)

Crinetics Pharmaceuticals, Inc. to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at the North American Neuroendocrine Tumor Society Annual Meeting

Crinetics Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Crinetics Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $400 million.

We're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely

Chief Financial Officer notifies of intention to sell stock

Crinetics Pharmaceuticals, Inc. Submits New Drug Application for Paltusotine for the Treatment of Acromegaly

Crinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Crinetics Pharmaceuticals, Inc. Announces Marc Wilson Will Be Transitioning from His Role as Chief Financial Officer

Chief Financial Officer notifies of intention to sell stock

Crinetics Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024